Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Field and greenhouse application of an attract-and-kill formulation based on the yeast Hanseniaspora uvarum and the insecticide spinosad to control Drosophila suzukii in grapes.
Spitaler U, Cossu CS, Delle Donne L, Bianchi F, Rehermann G, Eisenstecken D, Castellan I, Duménil C, Angeli S, Robatscher P, Becher PG, Koschier EH, Schmidt S. Spitaler U, et al. Among authors: dumenil c. Pest Manag Sci. 2022 Mar;78(3):1287-1295. doi: 10.1002/ps.6748. Epub 2021 Dec 15. Pest Manag Sci. 2022. PMID: 34854220 Free PMC article.
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Pons-Tostivint E, Hulo P, Guardiolle V, Bodot L, Rabeau A, Porte M, Hiret S, Demontrond P, Curcio H, Boudoussier A, Veillon R, Mayenga M, Dumenil C, Chatellier T, Gourraud PA, Mazieres J, Bennouna J. Pons-Tostivint E, et al. Among authors: dumenil c. Cancer Immunol Immunother. 2023 Jun;72(6):1891-1892. doi: 10.1007/s00262-023-03405-7. Cancer Immunol Immunother. 2023. PMID: 36847863 Free PMC article. No abstract available.
Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Pons-Tostivint E, Hulo P, Guardiolle V, Bodot L, Rabeau A, Porte M, Hiret S, Demontrond P, Curcio H, Boudoussier A, Veillon R, Mayenga M, Dumenil C, Chatellier T, Gourraud PA, Mazieres J, Bennouna J. Pons-Tostivint E, et al. Among authors: dumenil c. Cancer Immunol Immunother. 2023 Jun;72(6):1881-1890. doi: 10.1007/s00262-022-03359-2. Epub 2023 Jan 24. Cancer Immunol Immunother. 2023. PMID: 36690799 Free PMC article.
Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab.
Talb J, Takam Kamga P, Mayenga M, Costantini A, Julié C, Dumenil C, Dumoulin J, Ouaknine J, Giraud V, Dujon C, Azarian R, Glaser C, Emile JF, Giroux Leprieur E. Talb J, et al. Among authors: dumenil c. Cancer Immunol Immunother. 2022 Nov;71(11):2791-2799. doi: 10.1007/s00262-022-03206-4. Epub 2022 Apr 18. Cancer Immunol Immunother. 2022. PMID: 35435450 Free PMC article.
Baseline Hedgehog Pathway Activation and Increase of Plasma Wnt1 Protein Are Associated with Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer.
Mehlman C, Takam Kamga P, Costantini A, Julié C, Dumenil C, Dumoulin J, Ouaknine J, Giraud V, Chinet T, Emile JF, Giroux Leprieur E. Mehlman C, et al. Among authors: dumenil c. Cancers (Basel). 2021 Mar 5;13(5):1107. doi: 10.3390/cancers13051107. Cancers (Basel). 2021. PMID: 33807552 Free PMC article.
Plasma Biomarkers Screening by Multiplex ELISA Assay in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Costantini A, Takam Kamga P, Julie C, Corjon A, Dumenil C, Dumoulin J, Ouaknine J, Giraud V, Chinet T, Rottman M, Emile JF, Giroux Leprieur E. Costantini A, et al. Among authors: dumenil c. Cancers (Basel). 2020 Dec 31;13(1):97. doi: 10.3390/cancers13010097. Cancers (Basel). 2020. PMID: 33396187 Free PMC article.
27 results